Core Viewpoint - Haoyuan Pharmaceutical announced the approval of a capital increase of 50 million yuan to its subsidiary, Ouchuang Biotechnology, for the implementation of the fundraising project "New Drug Technology R&D Center" [2] Group 1 - The fourth meeting of the Audit Committee of the fourth Board of Directors was held on November 19, 2025 [2] - The company plans to use part of the raised funds for the development of new drug technology [2] - The decision was made to support the subsidiary's project aimed at enhancing research and development capabilities [2]

Core Viewpoint - The company, Haoyuan Pharmaceutical, has approved a capital increase of 50 million yuan to its subsidiary, Ouchuang Biotechnology, for the implementation of a new drug technology research and development center project [1] Group 1 - The fourth meeting of the Audit Committee and the fourteenth meeting of the Board of Directors were held on November 19, 2025 [1] - The decision to use part of the raised funds for the capital increase was made during these meetings [1] - The funds will specifically support the "New Drug Technology R&D Center" project [1]

Summary of Key Points Core Viewpoint The report outlines the fundraising activities and the utilization of funds by Shanghai Haoyuan Pharmaceutical Co., Ltd. for the first half of 2025, detailing the amount raised, the allocation of funds, and the management of these funds. Group 1: Fundraising Overview - The company raised a total of RMB 822.35 million through the issuance of convertible bonds, with a maturity of 6 years and a face value of RMB 100 per bond [1][2]. - As of June 30, 2025, the balance in the fundraising account was RMB 420,589,058.15, which includes interest income after deducting fees [1][2]. Group 2: Fund Utilization - The net amount of funds raised was RMB 811,737,609.85, with RMB 311,050,738.57 allocated to investment projects and RMB 86 million used for cash management [1][2]. - The company has not used any idle funds for temporary working capital during the reporting period [2][3]. Group 3: Fund Management - The company established a dedicated account for the management of raised funds, ensuring compliance with regulations and maintaining transparency [1][2]. - A three-party supervision agreement was signed with banks and the sponsor to oversee the management of the funds [1][2]. Group 4: Project Updates - The company has approved the use of raised funds to replace pre-invested self-raised funds amounting to RMB 40,333,017.97 for specific projects [2][3]. - The timeline for certain projects has been extended, with the "High-end Pharmaceutical Intermediates and Raw Materials CDMO Industrialization Project" expected to reach operational status by June 2029 [3][4]. Group 5: Compliance and Reporting - The company has adhered to the regulatory requirements for fundraising and has accurately disclosed the status of fund utilization [3][4]. - No violations in the management of raised funds have been reported, and all disclosures have been made in a timely and accurate manner [3][4].